Menu

Investor & Media information

You are here

  1. Home
  2. Media and investors
  3. Investor & Media information

MorphoSys is strictly committed to the principle of fair disclosure. One of the most important foundations of our corporate communication is to inform all stakeholders simultaneously and comprehensively about the situation of the Company. We pay great attention to transparent and timely communication.

Corporate media releases

Date
Title

2019

  1. 31/01/2019
    MorphoSys Announces Settlement in Patent Lawsuit with Janssen and Genmab
  2. 26/01/2019
    Ad hoc: MorphoSys Announces That Its Patents Were Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
    No download available
  3. 17/01/2019
    MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Ulcerative Colitis

2018

  1. 17/12/2018
    MorphoSys AG: Corporate Calendar 2019
  2. 12/12/2018
    MorphoSys's Licensee Janssen Announces Data from the Phase 3 Head-to-Head Study ECLIPSE Demonstrating Superiority of Tremfya(R) vs. Cosentyx(R) as Measured by PASI 90 at Week 48 in the Treatment of Plaque Psoriasis
  3. 07/12/2018
    Ad hoc: MorphoSys Announces that According to a Presentation Title at an Upcoming Conference, Guselkumab Demonstrates Superior Long-Term Responses to Secukinumab at Week 48 in the Treatment of Moderate to Severe Psoriasis
    No download available
  4. 02/12/2018
    MorphoSys Presents Updated Data from L-MIND Study of MOR208 plus Lenalidomide in r/r DLBCL at ASH 2018
  5. 26/11/2018
    MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in Japan for the Treatment of Patients with Palmoplantar Pustulosis
  6. 19/11/2018
    MorphoSys Announces Its Licensee Janssen Initiated a Phase 2 Study (NOVA) to Evaluate Guselkumab in Hidradenitis Suppurativa
  7. 15/11/2018
    MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys's Novel Immuno-Oncology Agent MOR210

Pages

Order form for publications and reports

Ad-hoc releases

Date
Title

2017

  1. 13/07/2017
    Adhoc: MorphoSys Announces That Its Licensee Janssen Has Received US FDA Approval for Tremfya(TM) (Guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis
    No download available

2016

  1. 15/11/2016
    Ad hoc: MorphoSys Raises EUR 115 million in Private Placement
  2. 15/11/2016
    Ad hoc: MorphoSys to Raise Capital via a Private Placement of New Shares
  3. 01/10/2016
    Ad hoc: MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Guselkumab in Plaque Psoriasis
  4. 21/04/2016
    Ad hoc: MorphoSys Provides Update on Results From Partner's Phase 2b/3 RESILIENT Study of Bimagrumab
  5. 04/04/2016
    Ad hoc: MorphoSys Sues Janssen Biotech and Genmab for Patent Infringement
  6. 24/02/2016
    Ad hoc: MorphoSys Announces Share Buy-Back Program

2015

  1. 07/05/2015
    Ad hoc: MorphoSys Acquires Peptide Therapeutic Company Lanthio Pharma
  2. 08/04/2015
    Ad hoc: MorphoSys to Start Share Buy-Back Program
  3. 26/03/2015
    Ad hoc: MorphoSys and Celgene Mutually Agree to End MOR202 Collaboration and MorphoSys Updates its Financial Guidance for 2015

Pages

Presentations
and conferences

Friday, April 26, 2019 - 3:30pm
Webcast: Class of 2018 Biotech IPOs Investor Day

Dr. Simon Moroney will present the Company at the Class of 2018 Biotech IPOs Investor Day, New York, NY, USA, on Friday, April 26, 2019, at 3:30 pm EDT (9:30 pm CEST, 8:30 pm BST).
Go to Webcast...

Archive

Date
Title
MP3

2019

  1. 04/16/2019

    Presentation: Kempen Life Sciences Conference

  2. 03/14/2019

    Year-End 2018 Conference Call and Webcast

  3. 02/28/2019

    Webcast: 8th Annual Leerink Partners Global Healthcare Conference

  4. 01/21/2019

    Presentation: Kepler Chevreux German Corporate Conference

  5. 01/14/2019

    Presentation: Commerzbank German Investment Seminar 2019

  6. 01/09/2019

    Webcast: JPMorgan Annual Healthcare Conference 2019

2018

  1. 12/06/2018

    Presentation: Berenberg European Conference 2018

  2. 12/05/2018

    Webcast: Investor & Analyst Event

  3. 11/28/2018

    Presentation: Piper Jaffray Annual Healthcare Conference

  4. 11/26/2018

    Presentation: German Eigenkapitalforum

  5. 11/22/2018

    Presentation: Bryan Garnier 6th Annual Healthcare Conference

  6. 11/06/2018

    Conference Call and Webcast: Q3 2018 Financial Results

  7. 10/03/2018

    Webcast: Leerink Partners Roundtable Series: Rare Disease & Oncology

  8. 09/25/2018

    Presentation: Berenberg and Goldman Sachs Seventh German Corporate Conference

  9. 09/24/2018

    Presentation: Baader Investment Conference

  10. 09/07/2018

    Presentation: Goldman Sachs Eighth Annual Biotech Symposium

  11. 08/28/2018

    Presentation: Commerzbank Sector Conference

  12. 08/02/2018

    Conference Call and Webcast: Q2 2018 Financial Results

  13. 06/20/2018

    Webcast: JMP Securities Life Sciences Conference

  14. 06/06/2018

    Presentation: dbAccess Berlin

  15. 05/21/2018

    Presentation: UBS Global Healthcare Conference

  16. 05/03/2018

    Conference Call and Webcast: Q1 2018 Financial Results

Pages

Pictures

Management Board

Dr. Simon E. Moroney

Chief Executive Officer,
MorphoSys AG

Jens Holstein

Chief Financial Officer,
MorphoSys AG

Dr. Malte Peters

Chief Development Officer,
MorphoSys AG

Dr. Markus Enzelberger

Chief Scientific Officer,
MorphoSys AG

Technology

Ylanthia

Ylanthia technology

Slonomics

Slonomics technology

HuCAL

HuCAL antibody library

HuCAL

Scientist working with the HuCAL library

Lab shots

Antibody purification

Scientist in protein chemistry lab

Daily work

MorphoSys scientist working in laboratory

Scientist with petri dishes

MorphoSys scientist handling petri dishes

Cell culture experiment

MorphoSys scientist in cell culture lab

Miscellaneous

MorphoSys Building Planegg

View of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Building Planegg

Entrance of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Logo
MorphoSys Footage Video

Copyright notice: The photos provided for download on this website can be used free of charge in the context of editorial reporting with the indication of the photo credit "©MorphoSys AG".